{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:50:42Z","timestamp":1773424242444,"version":"3.50.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":291,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"DOI":"10.1002\/ejhf.3614","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T01:03:56Z","timestamp":1739495036000},"page":"623-627","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Silencers Versus Stabilizers in Amyloid Cardiomyopathy. Are We Asking the Wrong Questions?"],"prefix":"10.1093","volume":"27","author":[{"given":"Rodney H.","family":"Falk","sequence":"first","affiliation":[{"name":"Brigham and Women's Hospital Amyloidosis Program and Section of Cardiology, Brigham and Women's Hospital , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.M.","family":"Cuddy","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital Amyloidosis Program and Section of Cardiology, Brigham and Women's Hospital , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osnat","family":"Itzhaki Ben Zadok","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital Amyloidosis Program and Section of Cardiology, Brigham and Women's Hospital , Boston, MA ,","place":["USA"]},{"name":"School of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"2026010913022115900_ejhf3614-bib-0001","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1172\/JCI105266","article-title":"Preparation of I-131-labeled human serum prealbumin and its metabolism in normal and sick patients","volume":"44","author":"Socolow","year":"1965","journal-title":"J Clin Invest"},{"key":"2026010913022115900_ejhf3614-bib-0002","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026010913022115900_ejhf3614-bib-0003","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"2026010913022115900_ejhf3614-bib-0004","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/14656566.2018.1554648","article-title":"An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"20","author":"Plante-Bordeneuve","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"2026010913022115900_ejhf3614-bib-0005","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"2026010913022115900_ejhf3614-bib-0006","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ejhf.3138","article-title":"Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"26","author":"Garcia-Pavia","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026010913022115900_ejhf3614-bib-0007","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"2026010913022115900_ejhf3614-bib-0008","article-title":"Outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial","author":"Fontana","journal-title":"J Am Coll Cardiol"},{"key":"2026010913022115900_ejhf3614-bib-0009","doi-asserted-by":"crossref","first-page":"11618","DOI":"10.1021\/bi050700m","article-title":"Binding of amyloidogenic transthyretin to the plasma membrane alters membrane fluidity and induces neurotoxicity","volume":"44","author":"Hou","year":"2005","journal-title":"Biochemistry"},{"key":"2026010913022115900_ejhf3614-bib-0010","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026010913022115900_ejhf3614-bib-0011","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ejhf.3088","article-title":"Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?","volume":"26","author":"Razvi","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026010913022115900_ejhf3614-bib-0012","doi-asserted-by":"crossref","first-page":"20508","DOI":"10.1038\/s41598-024-71446-8","article-title":"Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy","volume":"14","author":"Iino","year":"2024","journal-title":"Sci Rep"},{"key":"2026010913022115900_ejhf3614-bib-0013","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4931","article-title":"Degradation versus fibrillogenesis, two alternative pathways modulated by seeds and glycosaminoglycans","volume":"33","author":"Verona","year":"2024","journal-title":"Protein Sci"},{"key":"2026010913022115900_ejhf3614-bib-0014","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1021\/bi301313b","article-title":"Age-related oxidative modifications of transthyretin modulate its amyloidogenicity","volume":"52","author":"Zhao","year":"2013","journal-title":"Biochemistry"},{"key":"2026010913022115900_ejhf3614-bib-0015","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15041129","article-title":"Transthyretin stabilizers and seeding inhibitors as therapies for amyloid transthyretin cardiomyopathy","volume":"15","author":"Morfino","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026010913022115900_ejhf3614-bib-0016","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ejhf.2808","article-title":"Variant and wild type transthyretin amyloidosis: Two sides of the same coin or different currencies in different pockets?","volume":"25","author":"Itzhaki Ben Zadok","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026010913022115900_ejhf3614-bib-0017","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/13506129.2020.1808783","article-title":"Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma","volume":"28","author":"Nelson","year":"2021","journal-title":"Amyloid"},{"key":"2026010913022115900_ejhf3614-bib-0018","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020358","article-title":"Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis","volume":"10","author":"Pucci","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026010913022115900_ejhf3614-bib-0019","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913022115900_ejhf3614-bib-0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"key":"2026010913022115900_ejhf3614-bib-0021","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.jcmg.2023.07.007","article-title":"Cardiac amyloid quantification using (124)I-evuzamitide (124I-P5+14) versus 18F-florbetapir: A pilot PET\/CT study","volume":"16","author":"Clerc","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026010913022115900_ejhf3614-bib-0022","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1053\/j.semnuclmed.2024.05.012","article-title":"Radionuclide imaging of cardiac amyloidosis: An update and future aspects","volume":"54","author":"Clerc","year":"2024","journal-title":"Semin Nucl Med"},{"key":"2026010913022115900_ejhf3614-bib-0023","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.jcmg.2022.06.004","article-title":"Feasibility of 68Ga-labeled fibroblast activation protein inhibitor PET\/CT in light-chain cardiac amyloidosis","volume":"15","author":"Wang","year":"2022","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/4\/623\/65242910\/eurjhf_27_4_623.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/4\/623\/65242910\/eurjhf_27_4_623.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:02:37Z","timestamp":1767981757000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/4\/623\/8316349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2,13]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3614","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"2024-11-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}